We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?
Read MoreHide Full Article
Revolution Medicines, Inc. (RVMD - Free Report) shares ended the last trading session 11% higher at $43.92. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 0.7% loss over the past four weeks.
The sudden soaring of the stock price can be attributed to the positive investor mindset regarding the progress in the development of Revolution's lead investigational candidate, RMC-6236. The company is currently evaluating RMC-6236 as a monotherapy as well as in combination with other agents in seprate early-stage studies across a variety of oncology indications. Revolution's clinical-stage pipeline also comprises two other early-stage candidates, being devolped for solid tumour indications.
This company is expected to post quarterly loss of $0.75 per share in its upcoming report, which represents a year-over-year change of +18.5%. Revenues are expected to be $5.25 million, up 37.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Revolution Medicines, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on RVMD going forward to see if this recent jump can turn into more strength down the road.
Revolution Medicines is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Assertio (ASRT - Free Report) , finished the last trading session 8.1% higher at $1.60. ASRT has returned 34.5% over the past month.
Assertio's consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.02. Compared to the company's year-ago EPS, this represents a change of -115.4%. Assertio currently boasts a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?
Revolution Medicines, Inc. (RVMD - Free Report) shares ended the last trading session 11% higher at $43.92. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 0.7% loss over the past four weeks.
The sudden soaring of the stock price can be attributed to the positive investor mindset regarding the progress in the development of Revolution's lead investigational candidate, RMC-6236. The company is currently evaluating RMC-6236 as a monotherapy as well as in combination with other agents in seprate early-stage studies across a variety of oncology indications. Revolution's clinical-stage pipeline also comprises two other early-stage candidates, being devolped for solid tumour indications.
This company is expected to post quarterly loss of $0.75 per share in its upcoming report, which represents a year-over-year change of +18.5%. Revenues are expected to be $5.25 million, up 37.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Revolution Medicines, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on RVMD going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Revolution Medicines is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Assertio (ASRT - Free Report) , finished the last trading session 8.1% higher at $1.60. ASRT has returned 34.5% over the past month.
Assertio's consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.02. Compared to the company's year-ago EPS, this represents a change of -115.4%. Assertio currently boasts a Zacks Rank of #3 (Hold).